alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 15,951–15,975 of 27,146 studies marked Peer-reviewed (page 639 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Expert opinion on Alzheimer's disease diagnostics and management in Central Eastern European countries representing 88 million population

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026-09-09

The expert panel from Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia discussed the current situation of various topics related to the diagnostics, general management and treatment of Alzheimer's disease (AD) in these Central Eastern European (CEE) countries, representing around 88 million population. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Effect of choline alfoscerate in older adult patients with dementia: an observational study from the claims data of national health insurance

✓ Peer-reviewed alzhub usefulness score 44 out of 100. BMC geriatrics 2024-11-16

Choline alfoscerate, a cholinergic precursor with limited evidence of efficacy in dementia management, has been used for various cognitive impairments in Korea. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Patient cognitive impairment associated with higher home health care delivery costs

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Health services research 2021-12-17

To assess whether home health agencies incur significantly higher care delivery costs for patients with cognitive impairment across three timeframes relevant to home health payment policy. 2 key findings →

Participants: 1,214 Evidence: low

Full summary, score breakdown and related studies → Original source

Nursing Home Alzheimer's Special Care Units: Geographic Location Matters

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of the American Medical Directors Association 2021-08-20

Limited data suggest nursing home (NH) Alzheimer's special care units (ASCUs) may improve care and outcomes among residents with dementia. 5 key findings →

Design: cross-sectional Participants: 13,207 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Expanding Prior Authorization in Traditional Medicare—The WISeR Model

✓ Peer-reviewed alzhub usefulness score 44 out of 100. JAMA 2025-10-28

This Viewpoint discusses the Wasteful and Inappropriate Service Reduction (WISeR) model, a new payment model announced by the Centers for Medicare & Medicaid Services Innovation Center to broaden prior authorization in traditional Medicare. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans

✓ Peer-reviewed alzhub usefulness score 44 out of 100. JAMA Network Open 2025-08-29

This cross-sectional study examines trends in coverage of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide, and prior authorization requirements among Medicare Part D beneficiaries. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2013-07-16

Alzheimer's disease (AD) is the most common type of dementia accounting for 60-80% of the reported cases. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of immunology (Baltimore, Md. : 1950) 2020-01-20

Individuals with Down syndrome (DS) develop Alzheimer's disease (AD)-related neuropathology, characterized by amyloid plaques with amyloid β (Aβ) and neurofibrillary tangles with tau accumulation. 3 key findings →

Design: clinical trial Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Archives of neurology 2001-03-01

All patients taking donepezil completed the 30 days of treatment without adverse effects. 3 key findings →

Design: clinical trial Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Aluminum and Alzheimer's disease in the 21st century: An umbrella review of evidence and controversies

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurotoxicology 2026-07-24

The potential role of aluminum (Al) in the onset and progression of Alzheimer disease (AD) remains among the most enduring and divisive controversies in environmental neurotoxicology. 2 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A Systematic Review to Evaluate the Effect of Neflamapimod on Cognitive Function and Progression of Dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurology India 2026-01-09

Treatment options for dementia mainly comprise of symptomatic treatment, as no disease-modifying therapy currently exists that directly reduces the pathology. 3 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Downregulation of synapse-associated protein expression and loss of homeostatic microglial control in cerebrospinal fluid of infectious patients with delirium and patients with Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Brain, behavior, and immunity 2020-06-24

Delirium is a complex and multifactorial condition associated with long-term cognitive decline. 4 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer Disease & Associated Disorders 1997

This article reports the development and psychometric properties of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC).

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurobiology of Aging 1998-03-01

The ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically-confirmed cases; it should have a sensitivity >80% for detecting AD and a specificity of >80% for distinguishing other dementias; it should be reliable, reproducible, non-invasive, simple to perform, and inexpensive.

Full summary, score breakdown and related studies → Original source Free full text

Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005-12-01

Of the simplified methods for PIB analysis examined, CAR90 provided DVR measures that were most comparable to ART90; CER90 was the most reproducible and SUVR90 produced the largest effect size.

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed